Alteogen Inc.
196170
株式のランク
#1917
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
株価
$159.04
時価総額
$11.07B
変化（1日）
-2.95%
変化（1年）
-48.94%
国
KR
取引 Alteogen Inc. (196170)
カテゴリー
Healthcare
Alteogen Inc.（196170）の配当履歴
Alteogen Inc.（証券コード：196170）は合計で1回の配当を行いました。
すべての配当の合計（株式分割調整済み）は：$371.00
配当利回り（TTM）：0.0018
すべての配当の合計（株式分割調整済み）は：$371.00
配当利回り（TTM）：0.0018
2025から2026までのAlteogen Inc.（196170）の配当履歴
年間配当支払い
| 年 | 配当（株式分割調整済み） | 変化 |
|---|---|---|
| 2026 (TTM) | $371.00 | 0.00% |
| 2025 | $371.00 | 0.00% |
すべての配当支払いの一覧
| 年 | 配当 | 変化 |
|---|---|---|
| 2026 (TTM) | $371.00 | 0.00% |
| 2025 | $371.00 | 0.00% |
同業他社や競合企業の配当履歴
| 企業 | 配当支払い回数 | 国 |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 64.00% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
